ASINEX Ltd. And SIENABIOTECH Announce Lead Generation Collaboration
10/19/2005 5:10:38 PM
ASINEX Ltd, a worldwide leader in lead generation and lead optimization, will perform computational work for SIENABIOTECH S.p.A., an integrated drug discovery company.
ASINEX's computational department based on the information provided by SIENABIOTECH (undisclosed target & undisclosed set of small molecules active toward such target) will create different pharmacophore models and use the results to rank the whole in-house ASINEX library (Platinum Collection 120,000 compounds) based on the resulting docking score.
Georg C. Terstappen, V.P. Discovery Research of SIENABIOTECH said "Through this collaboration we expect to enhance the efficiency of our integrated drug discovery process which employs state-of-the-art platform technologies. Using ASINEX' compound collection, flexible docking and de novo ligand design technologies, we believe we can increase the chances of identifying high-quality leads."
"ASINEX's computational team, with their efficient lead generation and drug design solutions, have proven to be a creative partner for biotech companies. Our computational department is a part of ASINEX's 'chemistry driven' integrated drug discovery service. Today we are delighted to announce ASINEX's deal with Sienabiotech and we are looking forward to establish a long-term relationship which will also include chemistry services", said Dmitri Genis, ASINEX CEO
comments powered by